title: [Edoxaban (LIXIANA®) : new oral anticoagulant forthetreatment and secondary prevention of thromboembolic disease].
abstract: Edoxaban (Lixiana®) is a new oral anticoagulant that selectively inhibits Xa coagulation factor. It was carefully evaluated in the treatment and secondary prevention of deep venous thrombosis and pulmonary embolism in the Hokusai-VTE trial and in the prevention of systemic and cerebral embolisms in patients with non valvular atrial fibrillation in the ENGAGE AF-TIMI 48 trial. In both studies, edoxaban has proven its non-inferiority regarding its efficacy compared with warfarin as reference treatment while demonstrating a superiority regarding safety. Especially, it was associated with a significantly lower incidence of major and/or non-major but clinically relevant bleeding episodes compared with warfarin, and a significant reduction in cerebral and fatal hemorrhages was shown in ENGAGE AF-TIMI 48. Edoxaban is prescribed at a dose of 60 mg once daily, which should be reduced to 30 mg once daily in patients with renal impairment (creatinine clearance between 15 and 50 ml/min), a body weight below or equal 60 kg and/or a concomitant therapy with some strong P-glycoprotein inhibitors. Lixiana® is reimbursed for the treatment and secondary prevention of venous thromboembolic disease as well as in patients with non valvular atrial fibrillation and the presence of at least another risk factor.
authors.affiliation: Service de Diabétologie, Nutrition et Maladies métaboliques et Unité de Pharmacologie clinique, CHU, Site du Sart Tilman, Liège, Belgique.
authors.forename: A J
authors.initials: AJ
authors.lastname: Scheen
authors.affiliation: GIGA Cardiovascular Sciences, Heart Valve Clinic. Université de Liège.|Service de Cardiologie, CHU, Site du Sart Tilman, Liège, Belgique.
authors.forename: P
authors.initials: P
authors.lastname: Lancellotti
keywords:  Anticoagulant ;  Atrial fibrillation ;  Edoxaban ;  Pulmonary embolism ;  Venous thromboembolism